These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 25367763

  • 1. Differential impact of bortezomib on HL-60 and K562 cells.
    Kliková K, Štefaniková A, Pilchová I, Hatok J, Chudý P, Chudej J, Dobrota D, Račay P.
    Gen Physiol Biophys; 2015 Jan; 34(1):33-42. PubMed ID: 25367763
    [Abstract] [Full Text] [Related]

  • 2. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
    Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, Chen KF.
    Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
    [Abstract] [Full Text] [Related]

  • 3. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [Abstract] [Full Text] [Related]

  • 4. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.
    Shay KP, Wang Z, Xing PX, McKenzie IF, Magnuson NS.
    Mol Cancer Res; 2005 Mar; 3(3):170-81. PubMed ID: 15798097
    [Abstract] [Full Text] [Related]

  • 5. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 6. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    Zheng B, Zhou R, Gong Y, Yang X, Shan Q.
    Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
    [Abstract] [Full Text] [Related]

  • 8. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Ottosson-Wadlund A, Ceder R, Preta G, Pokrovskaja K, Grafström RC, Heyman M, Söderhäll S, Grandér D, Hedenfalk I, Robertson JD, Fadeel B.
    Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
    [Abstract] [Full Text] [Related]

  • 9. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 10. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC.
    Apoptosis; 2004 Mar; 9(2):149-55. PubMed ID: 15004512
    [Abstract] [Full Text] [Related]

  • 11. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 12. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 13. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
    Lü S, Chen Z, Yang J, Chen L, Zhou H, Xu X, Li J, Han F, Wang J.
    Int J Lab Hematol; 2010 Feb 21; 32(1 Pt 1):e123-31. PubMed ID: 19254348
    [Abstract] [Full Text] [Related]

  • 14. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL, Chen GQ.
    Leukemia; 2007 Jul 21; 21(7):1488-95. PubMed ID: 17495969
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.
    Clin Cancer Res; 2007 Nov 01; 13(21):6469-78. PubMed ID: 17975159
    [Abstract] [Full Text] [Related]

  • 16. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ.
    Clin Cancer Res; 2003 Oct 01; 9(12):4570-7. PubMed ID: 14555532
    [Abstract] [Full Text] [Related]

  • 17. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
    Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC.
    Cancer Res; 2003 Oct 01; 63(19):6174-7. PubMed ID: 14559800
    [Abstract] [Full Text] [Related]

  • 18. Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
    Li YC, Wang HH, Liao AJ, Fu BB, Zhang R, Li J, Yang Y, Liu ZG, Yang W.
    Eur Rev Med Pharmacol Sci; 2014 Oct 01; 18(10):1465-72. PubMed ID: 24899604
    [Abstract] [Full Text] [Related]

  • 19. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 20. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
    Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L, Mattii L, Battolla B, Capodanno A, Collecchi P, Veroni F, Simi P, Piaggi S, Casini A, Petrini M.
    Leuk Res; 2008 Jan 15; 32(1):103-12. PubMed ID: 17629554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.